Skip to content

Medical emergency? What to do

Heart experts say Merck arthritis drug too risky

3-RXPublished April 7, 20073 min read

Key points

  • Two prominent U.S. heart experts said studies of Merck & Co.
  • Nissen and Furberg said in interviews they were concerned that patients taking Arcoxia in a large international trial had a higher incidence of edema, elevated blood pressure and congestive heart failure than patients taking the standard treatment, diclofenac.
  • "This is a genie I don't want to see let out of the bottle," said Nissen, a recent president of the American College of Cardiology who predicted the FDA will refuse to approve the medicine.
  • "The product has been evaluated and re-evaluated by regulators in 63 countries, including the European Union," said Loder.

Two prominent U.S. heart experts said studies of Merck & Co. Inc. arthritis drug Arcoxia revealed risks that should prevent its approval in the United States and that the drug posed unacceptable dangers in the 63 countries where it is already sold.

The concerns were expressed on Thursday by Steven Nissen, head of cardiology at the Cleveland Clinic, and Dr. Curt Furberg, a professor of public health at Wake Forest University who is a member of the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration.

Nissen and Furberg said in interviews they were concerned that patients taking Arcoxia in a large international trial had a higher incidence of edema, elevated blood pressure and congestive heart failure than patients taking the standard treatment, diclofenac.

"All versions of Arcoxia should be taken off the market now," said Furberg. He and Nissen had been outspoken critics of Merck's older arthritis drug, Vioxx, before it was withdrawn in September 2004 based on evidence of heart attacks and strokes in long-term users.

"This is a genie I don't want to see let out of the bottle," said Nissen, a recent president of the American College of Cardiology who predicted the FDA will refuse to approve the medicine.

BENEFITS VS RISK

Merck spokesman Chris Loder said he disagreed with Nissen's and Furberg's assessment.

"The product has been evaluated and re-evaluated by regulators in 63 countries, including the European Union," said Loder. He said regulators continue to believe the drug's benefits outweigh its risks.

Arcoxia, which works through the same mechanism as Vioxx, is awaiting U.S. approval for treatment of osteoarthritis and had 2006 global sales of $265 million.

The so-called "MEDAL" international Arcoxia trial, whose more than 34,000 participants make it one of the largest cardiovascular safety studies ever conducted, showed that patients taking Arcoxia had a similar number of heart attacks and strokes as those taking diclofenac. The drug thereby met its primary goal of the study.

But more than twice as many arthritis patients taking the highest 90-milligram dose of Arcoxia developed congestive heart failure -- a dangerous condition in which the heart is unable to adequately pump blood -- than those taking diclofenac.

Moreover, roughly twice as many patients on the 90 milligram dose of Arcoxia dropped out of the trial because of edema, swollen tissues that are also a sign of possible heart damage.

That is the approved dose overseas for rheumatoid arthritis, the potentially crippling and less-common inherited form of arthritis. Smaller 30-milligram and 60-milligram doses are used to treat osteoarthritis, the more common form of arthritis caused by wear and tear of joints.

Similarly, roughly twice as many patients given the 90-milligram dose of Arcoxia dropped out of the trial due to increases in blood pressure. And a significantly higher percentage taking the 60-milligram dose of Arcoxia also dropped out due to elevated blood pressure.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Drug Abuse

Statin label to carry diabetes warning

All statin labels will now include a warning about a small increased risk for elevated blood glucose levels and possible problems with transient memory and cognition, the FDA announced today. The agency will also…

2 min read

Heart

10 Risk Factors for Heart Disease

Heart disease is the number one killer in the world. Several factors that increase the risk for heart disease have been identified by the American Heart Association. Scientific studies have shown significant risk…

5 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.